NTRK1 and cancer: In a range of human cancers activating mutations in receptor tyrosine kinases (RTKs), RAS, BRAF and more rarely CRAF and MEK1/2 results in de-regulated ERK1/2 activation [10] that drives the acquisition and maintenance of key cancer hallmarks.